Researchers have developed a new type of sensor that acts like Velcro® for prostate cancer cells, sticking them to a modified frosted glass slide, like those used in science classes, so that they can be identified from blood samples. The low-cost method, reported in ACS Applied Materials & Interfaces, could help doctors better diagnose and monitor the disease.
In men with prostate cancer, some tumor cells exit the prostate gland and circulate in the blood. Detecting these cells could enable diagnosis at an earlier stage or help doctors assess whether treatment is effective. However, because circulating tumor cells are present in very small numbers, finding them can be a challenge. Previous sensors have been expensive and difficult to make. So Shudong Zhang and Shutao Wang wanted do develop a simpler, more cost-effective way to monitor prostate cancer cells in the blood.
The researchers based their device on frosted glass microscope slides, commonplace in high school science classes. The frosted area, which is used to hold and label the slide, is a sandblasted surface with tiny depressions. The researchers added a solution to the frosted slides that caused silica nanowires to grow on their surfaces, then they dangled antibodies that recognized prostate cancer cells from the nanowires. After getting captured by the antibodies, circulating tumor cells became trapped in the depressions on the slide and tangled up within the nanowires, similar to the interlocking surfaces of Velcro®. The team could then visualize the cancer cells with microscopy, and found that the device had a capture efficiency on par with other approaches, they say. When the researchers tested blood samples from prostate cancer patients, the devices detected as few as 10 tumor cells in 1 milliliter of blood.
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer on February 18, 2019 at 3:02 pm
Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer. Patients ... […]
- Dr. Rayford on the Racial Genomics of Prostate Cancer on February 18, 2019 at 3:00 pm
Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prost... […]
- Certain Factors Impact Treatment Selection in Advanced Prostate Cancer on February 18, 2019 at 7:31 am
A patient’s race, income level, geographic area of residence, and whether management is conducted by a medical oncologist or a urologist may significantly influence the type of treatment administered ... […]
- New nanomedicines for a more efficient and less aggressive treatment of prostate cancer on February 18, 2019 at 6:03 am
In Europe, prostate cancer is the most common type of cancer among men with an incidence greater than 100 cases per 100,000 individuals. Furthermore, it is currently the second most common cause ... […]
- Researchers identify protein that contributes to racial disparities in prostate cancer on February 18, 2019 at 5:06 am
Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African-Americans than in Caucasian-Americans, but ... […]
- Prostate cancer: a tale of two sides on February 18, 2019 at 3:59 am
Understanding the disparities between a surgeon and patient experience is valuable for both. And what patient is better placed to describe their prostate cancer journey than Stephen Fry? One of the mo... […]
- Circulating tumor cell count may be an effective surrogate endpoint for OS in prostate cancer on February 15, 2019 at 2:04 pm
SAN FRANCISCO — A reduction to no circulating tumor cells at week 13 appeared to be a stronger indicator of survival outcomes than a 50% or greater reduction in PSA from baseline in phase 2 trials of ... […]
- More women reach the top at Illinois hospitals • Prostate cancer drug passes critical test on February 15, 2019 at 3:15 am
Illinois hospitals outpace the rest when it comes to female leadership. Women hold 30 percent of the CEO jobs at the state’s 206 hospitals, the Illinois Health and Hospital Association says. That’s co... […]
- Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors on February 15, 2019 at 1:10 am
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical t... […]
via Bing News